Overview

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Status:
Terminated
Trial end date:
2009-05-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and toxicity and feasibility of double umbilical cord blood transplantation (DUCBT) in patients with selected malignant and non-malignant, and to quantify the percentage and donor sources of mixed donor chimerism following DUCBT in patients with selected malignant and non-malignant disorders.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Columbia University
Treatments:
Alemtuzumab
Antilymphocyte Serum
Busulfan
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Fosphenytoin
Melphalan
Phenytoin
Thiotepa
Thymoglobulin
Vidarabine